Table 2.
Laboratory data of 26 patients at both acute and convalescent stage and that of 20 healthy controls
| Acute | Convalescence | Control | |
|---|---|---|---|
| Haematological and serological parameter | |||
| Leucocytes (mm3) | 11 001·9 ± 635·8* | 6790·0 ± 374·8 | ND |
| Neutrophils (%) | 63·4 ± 2·6* | 46·6 ± 3·0 | ND |
| Lymphocytes (%) | 33·8 ± 3·5 | 45·0 ± 2·9 | ND |
| Platelet count ( × 103/mm3) | 384·9 ± 16·6* | 311·4 ± 12·1 | ND |
| Elevation of CRP (no./total)† | 11/23* | 0/25 | ND |
| C3 (mg/dl) | 115·6 ± 3·1* | 100·8 ± 4·4 | 116·1 ± 3·7 |
| C4 (mg/dl) | 33·6 ± 2·5* | 25·1 ± 2·5 | 23·7 ± 1·5 |
| IgG (mg/dl) | 1133·2 ± 62·1 | 1072·2 ± 53·6 | 1071·9 ± 68·2 |
| IgA (mg/dl) | 269·4 ± 18·4* | 210·4 ± 21·9 | 170·8 ± 15·9 |
| IgM (mg/dl) | 181·8 ± 14·9 | 156·7 ± 12·8 | 181·1 ± 13·7 |
| TGF-β (ng/dl) | 32·0 ± 4·6 | 41·9 ± 5·1 | 30·4 ± 4·6 |
| Elevation of ASLO (no./total)‡ | 19/26* | 11/26 | 0/20 |
| Phenotype analysis of lymphocyte | |||
| T cell | 70·3 ± 1·8 | 71·9 ± 1·3 | 65·0 ± 1·6 |
| B cell | 17·3 ± 1·5 | 14·9 ± 0·8 | 15·2 ± 1·2 |
| CD4+ T cell | 35·8 ± 1·8 | 35·7 ± 1·6 | 32·0 ± 2·5 |
| CD8+ B cell | 27·6 ± 1·5 | 14·8 ± 1·1 | 12·5 ± 0·9 |
| CD45RA−CD4+ T cell | 15·2 ± 1·8 | 14·8 ± 1·1 | 12·5 ± 0·9 |
| CD45RA+CD4+ T cell | 20·7 ± 2·0 | 20·8 ± 1·5 | 19·5 ± 2·4 |
| αβ-T cell | 57·5 ± 2·1 | 59·3 ± 1·3 | ND |
| γδ-T cell | 7·5 ± 0·8 | 8·4 ± 0·7 | ND |
| NK cell | 10·1 ± 1·5 | 11·0 ± 1·5 | 13·1 ± 1·8 |
| CD5+ B cell | 8·2 ± 1·0 | 6·6 ± 0·5 | 8·9 ± 1·0 |
Values are presented as mean ±s.e.m.
ND, Not done.
*
P < 0·05 for differences between acute and convalescent stage.
†
Normal value of CRP: < 0·09.
‡
Anti-streptolysin O (ASLO) level >58 U/ml was viewed as elevated.